Corporate Finance
Bergs Securities acted as Sole Manager to Observit in its SEK 26 million directed share issue to Eiffel Investment Group
Bergs Securities acted as sole manager and bookrunner to Modus Therapeutics Holding AB in its oversubscribed SEK 28 million rights issue
Corporate Finance
Bergs Securities acted as sole manager and bookrunner to Modus Therapeutics Holding AB in its oversubscribed SEK 28 million rights issue.
Modus Therapeutics Holding AB is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis/septic shock and other disorders with severe systemic inflammation such as severe malaria, as well as states of anemia, related to chronic inflammation such as kidney disease.
Related News
Corporate Finance
Bergs Securities acted as sole manager and bookrunner to Initiator Pharma Therapeutics in its SEK 56 million rights issue
Corporate Finance
Bergs Securities assisted Smart Eye in the exercise of an incentive program resulting in 497 280 newly issued shares of which around half was divested through a block trade